Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

UltraCAR-T Cells (PRGN-3007) in Treating patients with Advanced Hematologic and Solid Tumor Malignancies

Trial Status: administratively complete

This phase I/Ib trial test the safety, side effects, and best dose of ultraCAR-T cells (PRGN-3007) in treating patients with blood (hematologic) or solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). PRGN-3007 T cells are made from white blood cells that are removed from the patient. The cells are genetically modified to create a protein (called a chimeric antigen receptor or CAR) on the surface of T cells, a type of blood cell that fights infection and cancer cells. The hope is that the CAR on the T cells will bind to and kill cells that express ROR1, a molecule expressed on the surface of hematological and solid tumor cells.